Carolina Arthritis Associates

Recent papers from Carolina Arthritis Associates

1. The relationship between lean mass and protein intake in females of African and East Asian descentBMC Nutrition · 2026
2. Clinical utility of a multianalyte lupus risk score incorporating cell-bound complement activation products: a systematic evaluationLupus Science & Medicine · 2026
3. Toward Optimal Dosing in Systemic Lupus Erythematosus: The Case for Hydroxychloroquine Blood Level MonitoringArthritis Care & Research · 2026
4. Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritisRMD Open · 2024
5. Ab0868 How Do Early Disease Activity and Early Clinical Response Associate With Long-Term Outcomes With Ixekizumab in Radiographic Axial Spondyloarthritis?Annals of the Rheumatic Diseases · 2024
6. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA RegistryClinical Rheumatology · 2023
7. Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosusAnnals of the Rheumatic Diseases · 2022
8. The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor TherapyAnnals of Internal Medicine · 2021
9. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosusNature Communications · 2021
10. Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studiesArthritis Research & Therapy · 2021
11. Ixekizumab, With Or Without Concomitant Methotrexate, Improves Signs And Symptoms Of Psa: Week 52 Results From Spirit-P1 And Spirit-P2 Studies2020
12. Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H StudyRheumatology and Therapy · 2020
13. Ixekizumab, With Or Without Concomitant Methotrexate, Improves Signs And Symptoms Of Psa: Week 52 Results From Spirit-P1 And Spirit-P2 Studies2020
14. An emergent, high-fatality lung disease in systemic juvenile arthritis2019
15. Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension StudyRheumatology and Therapy · 2019
16. Musculoskeletal Ultrasound Scanning Protocol Consensus Statements on Scanning Conventions and Documentation in the USArthritis Care & Research · 2019
17. Sat0374 ixekizumab, With or Without Concomitant Methotrexate, Improves the Signs and Symptoms of Psa for Up to 52 Weeks of TreatmentAnnals of the Rheumatic Diseases · 2019
18. Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb TrialThe Journal of Rheumatology · 2018
19. 2015 American College of Rheumatology Workforce Study: Supply and Demand Projections of Adult Rheumatology Workforce, 2015–2030Arthritis Care & Research · 2018
20. Shear wave elastography and Afirma™ gene expression classifier in thyroid nodules with indeterminate cytology: a comparison studyEndocrine · 2018